acute ischemic stroke
Conditions
Interventions
Experimental group:Adjunctive Intra-arterial adenosine following successful endovascular thrombectomy
Sponsors
The First Affiliated Hospital of Army Medical University, PLA
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Aged >= 18 years; 2.Symptoms indicative of acute ischemic stroke in the post-circulation phase, with an onset time (last known normal) within 24 hours (isolated vertigo is not considered a symptom of onset), confirmed by CTA, MRA, or DSA imaging to show basilar artery occlusion or intracranial vertebral artery occlusion (specifically, when the basilar artery is supplied solely by a unilateral vertebral artery). 3.Prestroke mRS score 0 or 1; 4.NIHSS score on admission >= 6; 5.Successful endovascular thrombectomy (eTICI 2b50-3); 6.The patient or their legal representative is able to understand the purpose of the trial, voluntarily participate, and sign a written informed consent form;
Exclusion criteria
Exclusion criteria: 1.Imaging data indicated the presence of intracranial hemorrhage or cerebellar infarction which exhibited a pronounced mass effect; 2.Baseline imaging examination revealed extensive infarcts in the posterior circulation region, as defined by PC-ASPECTS 3.0; 9.Platelet 185 mmHg or diastolic pressure >110 mmHg, and cannot be controlled by antihypertensive drugs; 11.Pregnant or lactating patients; 12.Life expectancy is less than 1 year; 13.Current participation in another clinical trial; 14.Neurologists do not consider other special circumstances appropriate for participation in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of mRS score 0 to 1 at 90 (+/-7) days; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of mRS score 0 to 2 at 90 (+/-7) days;Proportion of mRS score 0 to 3 at 90 (+/-7) days;Shift in the distribution of mRS scores at 90 (+/-7) days;The change of the NIHSS score at 5–7 days after surgery or discharge ;European Quality Five-Dimension scale score at 90 (+/-7) days;symptomatic intracranial hemorrhage (sICH) within 48 h after treatment;All-cause mortality at 90 (+/-7) days; | — |
Countries
China
Contacts
Public ContactZhenhua Zhou
The First Affiliated Hospital of Army Medical University, PLA
Outcome results
None listed